Evonik Industries (EVK) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
AGM opened by the chairman, welcoming shareholders, representatives, media, and guests; meeting held virtually per legal statutes.
Formalities confirmed: proper convocation, publication, and compliance with statutory requirements; no additional motions or proposals submitted.
Technical instructions provided for virtual participation, including video communication, voting, and submission of motions.
Agenda initiated with submissions of annual and consolidated financial statements, management and supervisory board reports, and profit appropriation proposal.
Financial performance review
2023 marked by weak demand, persistent inflation, energy crisis, and global recession, leading to a profit warning and downward revision of forecasts.
Group sales fell 17% to EUR 15.3 billion; adjusted EBITDA dropped by one third to EUR 1.66 billion, within the target range.
Net income was negative for the first time, but adjusted earnings per share were EUR 0.79; free cash flow reached EUR 801 million, exceeding the previous year.
Sector-wide output and sales declined by 11% and 12% respectively; prices fell by 3% amid inflationary cost increases.
Board and executive committee updates
Supervisory board reviewed and approved financial statements and profit appropriation proposal; no objections raised.
Supervisory board focused on business development, strategic planning, and major projects such as the construction of a lipid plant in the USA and divestment of the Lülsdorf site.
New elections and constitution of the supervisory board in 2023; three new employee representatives introduced.
Committees renamed and restructured, notably the Investment and Sustainability Committee.
Latest events from Evonik Industries
- Q2 2026 adjusted EBITDA up 24% to €630M; 2026 guidance raised amid strong segment gains.EVK
Q2 20264 Aug 2026 - Q2 2026 EBITDA up 24%, FY outlook raised, and new dividend policy introduced.EVK
Company presentation4 Aug 2026 - Q3 adjusted EBITDA up 19%, margin at 15%, and 2024 outlook confirmed amid uncertainty.EVK
Q3 20249 Jul 2026 - Targeting €1bn EBITDA growth and 11% ROCE by 2027 through innovation, optimization, and sustainability.EVK
CMD 20258 Jul 2026 - Integrated innovation and sustainability drive growth in biosolutions, hydrogen, and recycling.EVK
Investor update10 Jun 2026 - Leadership changes, new dividend policy, and innovation-driven strategy amid global challenges.EVK
AGM 20263 Jun 2026 - Q1 2026 EBITDA exceeded forecasts, but sales and net income fell; outlook remains stable.EVK
Q1 202610 May 2026 - Q1 2026 outperformed expectations, with robust cash flow and FY guidance reaffirmed.EVK
Company presentation8 May 2026 - Achieved FY 2025 guidance with robust cash flow and a new dividend policy for future flexibility.EVK
Investor presentation4 Mar 2026